Sustained delivery of lidocaine into the cochlea using poly lactic/glycolic acid microparticles

Laryngoscope

Volumn 120, Issue 2, 2010, Pages 377-383

  Horie, Rie T ^a   Sakamoto, Tatsunori ^a   Nakagawa, Takayuki ^a   Tabata, Yasuhiko ^b   Okamura, Noboru ^c   Tomiyama, Naoki ^c   Tachibana, Mitsuhiro ^a   Ito, Juichi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Biomaterial; Drug delivery system; Inner ear; Poly lactic glycolic acid; Tinnitus

Indexed keywords

LIDOCAINE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COCHLEA FENESTRA; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; DRUG TISSUE LEVEL; FEMALE; GUINEA PIG; HEARING LOSS; IN VITRO STUDY; NONHUMAN; NYSTAGMUS; OTITIS; PERILYMPH; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ANESTHETICS, LOCAL; ANIMALS; BIOCOMPATIBLE MATERIALS; COCHLEA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EAR, MIDDLE; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; GUINEA PIGS; LACTIC ACID; LIDOCAINE; MICROSPHERES; POLYGLYCOLIC ACID; SURFACE PROPERTIES; VESTIBULAR FUNCTION TESTS;

EID: 76249084076     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20713     Document Type: Article

References (15)

1. Bauer CA. Mechanisms of tinnitus generation. Curr Opin Otolaryngol Head Neck Surg 2004;12:413-417.
2. Murai K, Tyler RS, Harker LA, Stouffer JL. Review of pharmacologic treatment of tinnitus. Am J Otol 1992;13:454-464.
3. Delucchi E. Transtympanic pilocaine in tinnitus. Int J Tinnitus 2000;6:37-40.
4. Sakata H, Kojima Y, Koyama S, Furuya N, Sakata E. Treatment of cochlear tinnitus with transtympanic infusion of 4% lidocaine into the tympanic cavity. Int J Tinnitus 2001;7:46-50.
5. Trellakis S, Lautermann J, Lehnerdt G. Lidocaine: neurobiological targets and effects on the auditory system. Prog Brain Res 2007;166:303-322.
6. Lee KY, Nakagawa T, Okano T, et al. Novel therapy for hearing loss: delivery of insulin-like growth factor 1 to the cochlea using gelatin hydrogel. Otol Neurotol 2007;28:976-981.
7. Chen PC, Park YJ, Chang LC, et al. Injectable microparticle-gel system for prolonged and localized lidocaine release. I. In vitro characterization. J Biomed Mater Res A 2004;70:412-419.
8. Magnusson AK, Tham R. Vestibulo-oculomotor behaviour in rats following a transient unilateral vestibular loss induced by lidocaine. Neuroscience 2003;120:1105-1114.
9. Thomson PD, Melmon KL, Richardson JA, et al. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 1973;78:499-508.
10. Tan J, Ruttiger L, Panford-Walsh R, et al. Tinnitus behavior and hearing function correlate with the reciprocal expression patterns of BDNF and Arg3.1/arc in auditory neurons following acoustic trauma. Neuroscience 2007;145:715-726.
11. Laurikainen E, Nuttall AL, Miller JM, Quirk WS, Virolainen E. Experimental basis for lidocaine therapy in cochlear disorders. Acta Otolaryngol 1992;112:800-809.
12. Englesson S, Larsson B, Lindquist NG, Lyttkens L, Stahle J. Accumulation of 14C-lidocaine in the inner ear. Preliminary clinical experience utilizing intravenous lidocaine in the treatment of severe tinnitus. Acta Otolaryngol 1976;82:297-300.
13. Laurikainen E, Lin X, Nuttall AL, Dolan DF. The mechanism and site of action of lidocaine hydrochloride in guinea pig inner ear. Acta Otolaryngol 1997;117:523-528.
14. Ruel J, Chabbert C, Nouvian R, et al. Salicylate enables cochlear arachidonic-acid-sensitive NMDA receptor responses. J Neurosci 2008;28:7313-7323.
15. Turner JG. Behavioral measures of tinnitus in laboratory animals. Prog Brain Res 2007;166:147-156.